SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3191403467> ?p ?o ?g. }

Showing items 1 to 100 of ±238 with 100 items per page.

W3191403467 endingPage "e636" @default.
W3191403467 startingPage "e627" @default.
W3191403467 abstract "Background Current guidelines recommend a risk-adjusted treatment strategy for the management of acute pulmonary embolism. This is a particular patient category for whom optimal treatment (anticoagulant treatment, reperfusion strategies, and duration of hospitalisation) is currently unknown. We investigated whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation for a short period of 72 h, followed by a switch to a direct oral anticoagulant (dabigatran), is effective and safe. Methods We did a multinational, multicentre, single-arm, phase 4 trial at 42 hospitals in Austria, Belgium, France, Germany, Italy, Netherlands, Romania, Slovenia, and Spain. Adult patients (aged ≥18 years) with symptomatic intermediate-risk pulmonary embolism, with or without deep-vein thrombosis, were enrolled. Patients received parenteral low-molecular-weight or unfractionated heparin for 72 h after diagnosis of pulmonary embolism before switching to oral dabigatran 150 mg twice per day following a standard clinical assessment. The primary outcome was recurrent symptomatic venous thromboembolism or pulmonary embolism-related death within 6 months. The primary and safety outcomes were assessed in the intention-to-treat population. The study was terminated early, as advised by the data safety and monitoring board, following sample size adaptation after the predefined interim analysis on Dec 18, 2018. This trial is registered with the EU Clinical Trials Register (EudraCT 2015-001830-12) and ClinicalTrials.gov (NCT02596555). Findings Between Jan 1, 2016, and July 31, 2019, 1418 patients with pulmonary embolism were screened, of whom 402 were enrolled and were included in the intention-to-treat analysis (median age was 69·5 years [IQR 60·0–78·0); 192 [48%] were women and 210 [52%] were men). Median follow-up was 217 days (IQR 210–224) and 370 (92%) patients adhered to the protocol. The primary outcome occurred in seven (2% [upper bound of right-sided 95% CI 3]; p<0·0001 for rejecting the null hypothesis) patients, with all events occurring in those with intermediate-high-risk pulmonary embolism (seven [3%; upper bound of right-sided 95% CI 5] of 283). At 6 months, 11 (3% [95% CI 1–5]) of 402 patients had at least one major bleeding event and 16 (4% [2–6]) had at least one clinically relevant non-major bleeding event; the only fatal haemorrhage occurred in one (<1%) patient before the switch to dabigatran. Interpretation A strategy of early switch from heparin to dabigatran following standard clinical assessment was effective and safe in patients with intermediate-risk pulmonary embolism. Our results can help to refine guideline recommendations for the initial treatment of acute intermediate-risk pulmonary embolism, optimising the use of resources and avoiding extended hospitalisation. Funding German Federal Ministry of Education and Research, University Medical Center Mainz, and Boehringer Ingelheim. Current guidelines recommend a risk-adjusted treatment strategy for the management of acute pulmonary embolism. This is a particular patient category for whom optimal treatment (anticoagulant treatment, reperfusion strategies, and duration of hospitalisation) is currently unknown. We investigated whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation for a short period of 72 h, followed by a switch to a direct oral anticoagulant (dabigatran), is effective and safe. We did a multinational, multicentre, single-arm, phase 4 trial at 42 hospitals in Austria, Belgium, France, Germany, Italy, Netherlands, Romania, Slovenia, and Spain. Adult patients (aged ≥18 years) with symptomatic intermediate-risk pulmonary embolism, with or without deep-vein thrombosis, were enrolled. Patients received parenteral low-molecular-weight or unfractionated heparin for 72 h after diagnosis of pulmonary embolism before switching to oral dabigatran 150 mg twice per day following a standard clinical assessment. The primary outcome was recurrent symptomatic venous thromboembolism or pulmonary embolism-related death within 6 months. The primary and safety outcomes were assessed in the intention-to-treat population. The study was terminated early, as advised by the data safety and monitoring board, following sample size adaptation after the predefined interim analysis on Dec 18, 2018. This trial is registered with the EU Clinical Trials Register (EudraCT 2015-001830-12) and ClinicalTrials.gov (NCT02596555). Between Jan 1, 2016, and July 31, 2019, 1418 patients with pulmonary embolism were screened, of whom 402 were enrolled and were included in the intention-to-treat analysis (median age was 69·5 years [IQR 60·0–78·0); 192 [48%] were women and 210 [52%] were men). Median follow-up was 217 days (IQR 210–224) and 370 (92%) patients adhered to the protocol. The primary outcome occurred in seven (2% [upper bound of right-sided 95% CI 3]; p<0·0001 for rejecting the null hypothesis) patients, with all events occurring in those with intermediate-high-risk pulmonary embolism (seven [3%; upper bound of right-sided 95% CI 5] of 283). At 6 months, 11 (3% [95% CI 1–5]) of 402 patients had at least one major bleeding event and 16 (4% [2–6]) had at least one clinically relevant non-major bleeding event; the only fatal haemorrhage occurred in one (<1%) patient before the switch to dabigatran. A strategy of early switch from heparin to dabigatran following standard clinical assessment was effective and safe in patients with intermediate-risk pulmonary embolism. Our results can help to refine guideline recommendations for the initial treatment of acute intermediate-risk pulmonary embolism, optimising the use of resources and avoiding extended hospitalisation." @default.
W3191403467 created "2021-08-16" @default.
W3191403467 creator A5000521035 @default.
W3191403467 creator A5001581013 @default.
W3191403467 creator A5002362593 @default.
W3191403467 creator A5003450562 @default.
W3191403467 creator A5007694037 @default.
W3191403467 creator A5007799685 @default.
W3191403467 creator A5009486477 @default.
W3191403467 creator A5010872053 @default.
W3191403467 creator A5011534196 @default.
W3191403467 creator A5015585782 @default.
W3191403467 creator A5021000995 @default.
W3191403467 creator A5021098089 @default.
W3191403467 creator A5021509121 @default.
W3191403467 creator A5021929797 @default.
W3191403467 creator A5022021799 @default.
W3191403467 creator A5025249336 @default.
W3191403467 creator A5025928709 @default.
W3191403467 creator A5026613773 @default.
W3191403467 creator A5026788917 @default.
W3191403467 creator A5031017432 @default.
W3191403467 creator A5031145016 @default.
W3191403467 creator A5031374547 @default.
W3191403467 creator A5032158326 @default.
W3191403467 creator A5032218282 @default.
W3191403467 creator A5032848672 @default.
W3191403467 creator A5035254382 @default.
W3191403467 creator A5036890928 @default.
W3191403467 creator A5038941926 @default.
W3191403467 creator A5039411863 @default.
W3191403467 creator A5040348969 @default.
W3191403467 creator A5040488831 @default.
W3191403467 creator A5040848081 @default.
W3191403467 creator A5042248757 @default.
W3191403467 creator A5045010479 @default.
W3191403467 creator A5045047622 @default.
W3191403467 creator A5045137769 @default.
W3191403467 creator A5046941977 @default.
W3191403467 creator A5050884728 @default.
W3191403467 creator A5053752784 @default.
W3191403467 creator A5054614012 @default.
W3191403467 creator A5055481748 @default.
W3191403467 creator A5056982955 @default.
W3191403467 creator A5060373225 @default.
W3191403467 creator A5065469571 @default.
W3191403467 creator A5066093039 @default.
W3191403467 creator A5067221476 @default.
W3191403467 creator A5067385718 @default.
W3191403467 creator A5067725875 @default.
W3191403467 creator A5069699839 @default.
W3191403467 creator A5070470290 @default.
W3191403467 creator A5070896792 @default.
W3191403467 creator A5073390275 @default.
W3191403467 creator A5074191286 @default.
W3191403467 creator A5075043010 @default.
W3191403467 creator A5076495125 @default.
W3191403467 creator A5077111909 @default.
W3191403467 creator A5077212270 @default.
W3191403467 creator A5077269359 @default.
W3191403467 creator A5078609671 @default.
W3191403467 creator A5079747950 @default.
W3191403467 creator A5081041579 @default.
W3191403467 creator A5081098974 @default.
W3191403467 creator A5081120942 @default.
W3191403467 creator A5084045526 @default.
W3191403467 creator A5086101965 @default.
W3191403467 creator A5087883382 @default.
W3191403467 creator A5088647237 @default.
W3191403467 creator A5089939086 @default.
W3191403467 creator A5090278878 @default.
W3191403467 date "2021-09-01" @default.
W3191403467 modified "2023-10-18" @default.
W3191403467 title "Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial" @default.
W3191403467 cites W1529942874 @default.
W3191403467 cites W2113561246 @default.
W3191403467 cites W2118092611 @default.
W3191403467 cites W2120203545 @default.
W3191403467 cites W2130199362 @default.
W3191403467 cites W2134430286 @default.
W3191403467 cites W2150979970 @default.
W3191403467 cites W2159007980 @default.
W3191403467 cites W2160625453 @default.
W3191403467 cites W2166402206 @default.
W3191403467 cites W2233919199 @default.
W3191403467 cites W2284688597 @default.
W3191403467 cites W2372521228 @default.
W3191403467 cites W2510857252 @default.
W3191403467 cites W2511180897 @default.
W3191403467 cites W2530021651 @default.
W3191403467 cites W2773269724 @default.
W3191403467 cites W2945776346 @default.
W3191403467 cites W2946408194 @default.
W3191403467 cites W2966973160 @default.
W3191403467 cites W2971121646 @default.
W3191403467 cites W2989714602 @default.
W3191403467 cites W2998804198 @default.
W3191403467 cites W3012952076 @default.